-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Novome Biotechnologies announced that it has reached a multi-year research cooperation and licensing agreement with Genentech, a subsidiary of Roche
Inflammatory bowel diseases include Crohn's disease and ulcerative colitis
Novome developed the GEMMs technology platform through engineering design of Lactococcus lactis, which is common in food
▲The mechanism of the GEMMs platform (picture source: Novome's official website)
According to the terms of the agreement, Novome will be responsible for the research activities of engineered bacteria until the start of supporting preclinical research authorized by the IND
Reference materials:
[1] Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease.
(The original text has been deleted)